1. Postmenopausal women using menopausal hormone therapy (MHT) achieved the most significant total body weight loss (19.9%) with tirzepatide compared with 15.6% in postmenopausal women not on MHT.
2. Premenopausal and perimenopausal women achieved similar weight reductions of approximately 18.6% to 18.7%, indicating tirzepatide’s consistent efficacy across reproductive stages.
3. Findings suggest a potential synergistic effect between MHT and tirzepatide on metabolic regulation and body composition in postmenopausal women.
4. Propensity-score matching adjusted for diabetes, prior weight-loss drug use, and baseline body mass index, supporting the robustness of observed differences.
5. The results highlight an opportunity for individualized obesity management in women, particularly those undergoing menopausal transition or receiving hormone therapy.

Source: 2025 Annual Meeting of The Menopause Society